doi: 10.1038/s41467-020-18764-3
Overall, these limitations might encourage the search of different approaches, which might combine a more favorable compliance and safety, with acceptable efficacy and with more affordable treatment regimens, and might be therefore particularly suited in a minority of patients experiencing one or more hindrances to PDE5i treatment
Some plans dont cover weight loss medications at all, and if thats the case, unfortunately, an appeal wont change the outcome, she says
The substantial cost differential highlights the importance of exploring NHS options first, particularly for patients who would struggle to sustain long-term private costs
And now it's sort of a back and forth within the field
Quick Answer: Lack of results with semaglutide at lower doses typically reflects insufficient time at therapeutic levels, subtherapeutic dosing, or individual variability requiring dose escalation